Skip to main content
. Author manuscript; available in PMC: 2024 Feb 17.
Published in final edited form as: Vaccine. 2023 Jan 31;41(8):1513–1523. doi: 10.1016/j.vaccine.2023.01.059

Table 1:

Demographics of Study Participants

All Participants (%)
N = 32		 ZEBOV Vaccine Experienced Participants (%)
N = 11		 ZEBOV Vaccine Naive Participants (%)
N = 21
Median Age in Years (Interquartile range) 40 (34.5, 46.8) 37 (34, 46) 42 (37, 47.5)
Gender
Female 17 (53.1%) 5 (45.5%) 12 (57.1%)
Male 15 (46.9%) 6 (54.5%) 9 (42.9%)
Prior Ebola Vaccine
None 21 (65.6%) 0 (0%) 21 (100%)
ChAd3-EBO-Za only 2 (6.3%) 2 (18.2%) 0 (0%)
ChAd3-EBO-Z with MVA-BN-Filob booster 9 (28.1%) 9 (81.8%) 0 (0%)

ChAd3-EBO-Z: replication-defective chimpanzee adenovirus 3 vector vaccine expressing ZEBOV-GP. MVA-BN-Filo: modified vaccinia Ankara virus expressing ZEBOV and other filovirus antigens (GPs from Marburg virus, Sudan virus, and Tai Forest virus).